Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid conditions secondary to immune deficiency. Infection also affects broad organ system function. Although current antiretroviral therapy (ART) reduces disease morbidity and mortality through effective control of peripheral viral load, restricted infection in HIV reservoirs including gut, lymphoid and central nervous system tissues, is not eliminated. What underlies these events is, in part, poor ART penetrance into each organ across tissue barriers, viral mutation and the longevity of infected cells. We posit that one means to improve these disease outcomes is through nanotechnology. To this end, this review discusses a broad range of cutting-edge nanomedicines and nanomedicine platforms that are or can be used to improve ART delivery. Discussion points include how polymer-drug conjugates, dendrimers, micelles, liposomes, solid lipid nanoparticles and polymeric nanoparticles can be harnessed to best yield cell-based delivery systems. When completely developed, such nanomedicine platforms have the potential to clear reservoirs of viral infection.

Original languageEnglish (US)
Pages (from-to)4186-4198
Number of pages13
JournalCurrent medicinal chemistry
Volume21
Issue number36
DOIs
StatePublished - Jan 1 2014

Fingerprint

Nanomedicine
Medical nanotechnology
Viruses
HIV
Virus Diseases
Nanoparticles
Tissue
Dendrimers
Nerve Tissue
Nanotechnology
Penetrance
Neurology
Micelles
Infection
Viral Load
Liposomes
Polymers
Therapeutics
Central Nervous System
Morbidity

Keywords

  • Dendrimers
  • Drug delivery systems
  • Gut associated lymphoid tissue
  • HIV
  • HIV reservoir targeted ART
  • Liposomes
  • Lymphoid tissues
  • Micelles
  • Nanomedicine
  • Polymeric nanoparticles

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. / Edagwa, Benson J; Zhou, Tian; McMillan, JoEllyn M; Liu, Xin Ming; Gendelman, Howard Eliot.

In: Current medicinal chemistry, Vol. 21, No. 36, 01.01.2014, p. 4186-4198.

Research output: Contribution to journalArticle

@article{6b6253a2366f4752a3339d1834912bcf,
title = "Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies",
abstract = "Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid conditions secondary to immune deficiency. Infection also affects broad organ system function. Although current antiretroviral therapy (ART) reduces disease morbidity and mortality through effective control of peripheral viral load, restricted infection in HIV reservoirs including gut, lymphoid and central nervous system tissues, is not eliminated. What underlies these events is, in part, poor ART penetrance into each organ across tissue barriers, viral mutation and the longevity of infected cells. We posit that one means to improve these disease outcomes is through nanotechnology. To this end, this review discusses a broad range of cutting-edge nanomedicines and nanomedicine platforms that are or can be used to improve ART delivery. Discussion points include how polymer-drug conjugates, dendrimers, micelles, liposomes, solid lipid nanoparticles and polymeric nanoparticles can be harnessed to best yield cell-based delivery systems. When completely developed, such nanomedicine platforms have the potential to clear reservoirs of viral infection.",
keywords = "Dendrimers, Drug delivery systems, Gut associated lymphoid tissue, HIV, HIV reservoir targeted ART, Liposomes, Lymphoid tissues, Micelles, Nanomedicine, Polymeric nanoparticles",
author = "Edagwa, {Benson J} and Tian Zhou and McMillan, {JoEllyn M} and Liu, {Xin Ming} and Gendelman, {Howard Eliot}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/0929867321666140826114135",
language = "English (US)",
volume = "21",
pages = "4186--4198",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "36",

}

TY - JOUR

T1 - Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies

AU - Edagwa, Benson J

AU - Zhou, Tian

AU - McMillan, JoEllyn M

AU - Liu, Xin Ming

AU - Gendelman, Howard Eliot

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid conditions secondary to immune deficiency. Infection also affects broad organ system function. Although current antiretroviral therapy (ART) reduces disease morbidity and mortality through effective control of peripheral viral load, restricted infection in HIV reservoirs including gut, lymphoid and central nervous system tissues, is not eliminated. What underlies these events is, in part, poor ART penetrance into each organ across tissue barriers, viral mutation and the longevity of infected cells. We posit that one means to improve these disease outcomes is through nanotechnology. To this end, this review discusses a broad range of cutting-edge nanomedicines and nanomedicine platforms that are or can be used to improve ART delivery. Discussion points include how polymer-drug conjugates, dendrimers, micelles, liposomes, solid lipid nanoparticles and polymeric nanoparticles can be harnessed to best yield cell-based delivery systems. When completely developed, such nanomedicine platforms have the potential to clear reservoirs of viral infection.

AB - Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid conditions secondary to immune deficiency. Infection also affects broad organ system function. Although current antiretroviral therapy (ART) reduces disease morbidity and mortality through effective control of peripheral viral load, restricted infection in HIV reservoirs including gut, lymphoid and central nervous system tissues, is not eliminated. What underlies these events is, in part, poor ART penetrance into each organ across tissue barriers, viral mutation and the longevity of infected cells. We posit that one means to improve these disease outcomes is through nanotechnology. To this end, this review discusses a broad range of cutting-edge nanomedicines and nanomedicine platforms that are or can be used to improve ART delivery. Discussion points include how polymer-drug conjugates, dendrimers, micelles, liposomes, solid lipid nanoparticles and polymeric nanoparticles can be harnessed to best yield cell-based delivery systems. When completely developed, such nanomedicine platforms have the potential to clear reservoirs of viral infection.

KW - Dendrimers

KW - Drug delivery systems

KW - Gut associated lymphoid tissue

KW - HIV

KW - HIV reservoir targeted ART

KW - Liposomes

KW - Lymphoid tissues

KW - Micelles

KW - Nanomedicine

KW - Polymeric nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84928674001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928674001&partnerID=8YFLogxK

U2 - 10.2174/0929867321666140826114135

DO - 10.2174/0929867321666140826114135

M3 - Article

C2 - 25174930

AN - SCOPUS:84928674001

VL - 21

SP - 4186

EP - 4198

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 36

ER -